Boston (May 2, 2024)”Allarity Therapeutics, Inc. (Allarity or the Company) (NASDAQ: ALLR), a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, today...
Boston (April 29, 2024) ” Allarity Therapeutics, Inc. (Allarity or the Company) (NASDAQ: ALLR), a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments,...
Boston (April 17, 2024)”Allarity Therapeutics, Inc. (Allarity or the Company) (NASDAQ: ALLR), a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, today...
Boston (April 4, 2024) ” Allarity Therapeutics, Inc. (Allarity or the Company) (NASDAQ: ALLR), a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, today...
The stenoparib Phase 2 monotherapy trial in advanced, recurrent ovarian cancer continues to show promise, prompting shift in resources to accelerate stenoparib development Further development of...
Boston (March 25, 2024) ” Allarity Therapeutics, Inc. (Allarity or the Company) (NASDAQ: ALLR), a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments,...
Allarity Therapeutics Reports Full Year 2023 Financial Results
Boston (February 28, 2024) ” Allarity Therapeutics, Inc. (Allarity or the Company) (NASDAQ: ALLR), a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments,...
Novartis ends license agreement for cancer drug with Allarity Therapeutics
Already reeling from the controversial termination of its CEO, Allarity Therapeutics has now been told that Novartis is rescinding the rights to a troubled cancer drug after the biotech failed to keep up with its payments.